Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Abstract. Circulating tumor cells (CTC) and tumor-derived Extracellular Vesicles (tdEV) loads are prognostic of survival in carcinoma patients. The current meth 
No comment yet.
Sign up to comment
Scoop.it!
From
http
-
November 30, 2017 8:43 AM
Panel provides for the most comprehensive coverage of single cell biomarkers for clinical trial research
Scoop.it!
The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking. Using established tools available in a CAP-accredited and CLIA-certified clinical laboratory, we quantified digital pathology features on 9,225 individual circulating tumor cells (CTCs) from 179 unique metastatic castration-resistant prostate cancer (mCRPC) patients to define phenotypically distinct cell types. Heterogeneity was quantified based on the diversity of cell types in individual patient samples using the Shannon index and associated with overall survival (OS) in the 145 specimens collected prior to initiation of second or later lines of therapy. Low CTC phenotypic heterogeneity was associated with better OS in patients treated with androgen receptor signaling inhibitors (ARSI), whereas high heterogeneity was associated with better OS in patients treated with taxane chemotherapy. Overall, the results show that quantifying CTC phenotypic heterogeneity can help inform the choice between ARSI and taxanes in mCRPC patients.
Scoop.it!
Circulating tumor cell (CTC) count is a major prognostic factor in metastatic breast cancer (MBC) and has been reported to be associated with thrombosis in short‐term studies on MBC patients.T
Gilbert C FAURE's insight:
Results/Conclusions With a median follow-up of 64 months [25-81 months], among the 142 patients included, 34 (24%) experienced a TE (Incidence rate: 8 TE/100 patient-years). The TE incidence rate was 13 TE/100 patient-years for the 80 patients with ≥1 CTC/7.5mL of blood before initiating first-line chemotherapy, versus only 4 TE/100 patient-years for the 62 CTC-negative patients. Fine-Gray multivariate analysis (with death as competing event) included age, Khorana score, and baseline lactate dehydrogenase and CTC levels: detectable CTC was the only factor significantly associated with an increased risk of TE (subdistribution hazard ratio (SHR) for patients with [1-4] CTC=3.1 95%CI[1.1;8.6]; SHR for patients with ≥5 CTC=1.4 95%CI[0.5;4.6]). This study shows that CTC detection before starting first-line chemotherapy is an independent risk factor for TE in MBC patients.
Scoop.it!
Epic Sciences is one of the coolest kids on the biopharma block, with a new $40 million Series D financing round and a whopping 42 industry partnerships built around its novel liquid biopsy platform. For a team of just 70, the San Diego startup is doing pretty well.
Scoop.it!
Circulating tumour cells (CTCs) have the potential to act as a source of tumour tissue for the measurement of pharmacodynamic biomarkers in early phase clinical trials.
Scoop.it!
Circulating tumor cells (CTCs) originate from tumor tissues and are associated with cancer prognosis.
Scoop.it!
Firmato l'accordo per la cessione a Menarini Silicon Biosystems del business CellSearch CTC
Scoop.it!
Small cell lung cancer (SCLC) is characterized by prevalent circulating tumour cells (CTCs), early metastasis and poor prognosis. We show that SCLC patients (37/38) have rare CTC subpopulations co-expressing vascular endothelial-cadherin (VE-cadherin
Scoop.it!
#liquidbiopsy based on #CTCs #CTDNA #miRNAs #exosomes. https://t.co/ZO5kWHuEVb
|
Scoop.it!
Finding needles in a haystack is the life-and-death job of San Diego’s Epic Sciences. The needles are extremely rare cancer cells that hide among the millions of normal cells in the blood of cancer patients.
Scoop.it!
Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay
Scoop.it!
Picking out circulating tumor cells (CTCs) from whole blood, known as liquid biopsy, should soon be a regular way to screen for cancer and to monitor patie
Scoop.it!
Much effort has been dedicated to developing circulating tumor cells (CTC) as a noninvasive cancer biopsy, but with limited success as yet. In this study, we combine a method for isolation of highly pure CTCs using immunomagnetic enrichment/fluorescence-activated cell sorting with advanced whole genome sequencing (WGS), based on long fragment read technology, to illustrate the utility of an accurate, comprehensive, phased, and quantitative genomic analysis platform for CTCs. Whole genomes of 34 CTCs from a patient with metastatic breast cancer were analyzed as 3,072 barcoded subgenomic compartments of long DNA. WGS resulted in a read coverage of 23× per cell and an ensemble call rate of >95%. These barcoded reads enabled accurate detection of somatic mutations present in as few as 12% of CTCs. We found in CTCs a total of 2,766 somatic single-nucleotide variants and 543 indels and multi-base substitutions, 23 of which altered amino acid sequences. Another 16,961 somatic single nucleotide variant and 8,408 indels and multi-base substitutions, 77 of which were nonsynonymous, were detected with varying degrees of prevalence across the 34 CTCs. On the basis of our whole genome data of mutations found in all CTCs, we identified driver mutations and the tissue of origin of these cells, suggesting personalized combination therapies beyond the scope of most gene panels. Taken together, our results show how advanced WGS of CTCs can lead to high-resolution analyses of cancers that can reliably guide personalized therapy. Cancer Res; 77(16); 4530–41. ©2017 AACR .
Scoop.it!
Intratumoral Cancer Cell Intravasation Can Occur Independent of Invasion into the Adjacent Stroma
Gilbert C FAURE's insight:
pdf article in cell reports
Scoop.it!
Circulating tumor cells were able to detect disease recurrence an average of 6 months before standard imaging.
Scoop.it!
The relevance of blood-based assays to monitor minimal residual disease (MRD) in non-metastatic prostate cancer (PCa) remains unclear. Proving that clinically relevant circulating tumor cells (CTCs) can be detected with available technologies could addres
Scoop.it!
Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application
Scoop.it!
Liquid biopsies: "circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), exosomes and microRNAs (miRNAs)" https://t.co/FHtyiQQ8yE
|
